Binosto — Medica
any FDA-approved indication(s)
Preferred products
- alendronate
- ibandronate
- risedronate
- risedronate delayed-release
- Atelvia
Initial criteria
- Patient has tried one Step 1 Product (alendronate 5, 10, 35, 40, or 70 mg tablets; ibandronate 150 mg tablets; risedronate 5, 30, 35, or 150 mg tablets; risedronate 35 mg delayed-release tablets) AND one Step 2 Product (Atelvia); OR
- For Binosto only: patient has a gastrostomy tube (G-tube); OR patient cannot swallow or has difficulty swallowing tablets or capsules.
Reauthorization criteria
- Continuation is clinically appropriate.
Approval duration
1 year